CiMaas, together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of € 1,48 million to further develop Natural Killer Cell therapy for breast cancer.
CiMaas is successful in expanding Natural Killer cells obtained from a small population in peripheral blood into very high numbers in just 2 weeks. This is directly applicable for clinical application in anti-cancer therapy.
Cimaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell (DC) vaccine against lung cancer. It concerns a loan of € 2.4 million.